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The p53 family regulates cell-cycle arrest, triggers apoptosis or is involved in repair of DNA damage. In the present study, we analysed
the expression of some p53 family proteins and their responses to chemoradiation therapy (CRT) in cases of oesophageal squamous
cell carcinoma (ESCC). We immunohistochemically investigated the relationship between p53, p53R2, and p21 expression in biopsy
specimens of untreated primary tumours and their clinical and histological responses to CRT in 62 patients with ESCC.
Chemoradiation therapy consisted of 5-fluorouracil plus cisplatin and 40Gy of radiation. The rates of clinical and histological
responses (complete or partial) to CRT were 71.0% (clinical) and 52.8% (histological). The rate of positive expression was 43.5% for
p53, 37.1% for p53R2, and 54.8% for p21 expression. Statistically significant correlations were found between p53 or p53R2
expression and favourable response to CRT (P¼0.0001 or 0.041 clinical, P¼0.016 or 0.0018 histological, respectively).
Furthermore, in p53-negative tumours, CRT was more effective in tumours with p53R2 negative expression than those with p53R2
positive expression (P¼0.0014). We demonstrated that the negative expression of p53 and p53R2 expression was closely related to
the effect of CRT and should predict the CRT outcome in patients with ESCC.
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Since the prognosis of patients with oesophageal squamous cell
carcinoma (ESCC) is still poor, various types of aggressive therapy
such as extended lymphadenectomy, radiotherapy, and che-
motherapy are being used (Naunheim et al, 1992; Baba et al,
1994). Chemoradiation therapy (CRT) for the treatment of
oesophageal cancer has been investigated since the 1980s, and
the combination of 5-fluorouracil (5-FU) and cisplatin has been
regarded as an enhancer of radiosensitivity (John et al, 1989).
Chemoradiation therapy is one of the most useful treatments for
ESCC (Nakano et al, 2001). As some patients have responded well
to CRT and others do not, it is important to predict the CRT
response from markers before beginning treatment.
From recent advances in fundamental research, many biological
markers concerning apoptosis, DNA repair, and the cell cycle have
been elucidated for their association with responses to CRT in
cases of ESCC. The effectiveness of CRT may be closely associated
with apoptosis (Thompson, 1995). The tumour suppressor gene
p53 regulates cell-cycle arrest and triggers apoptosis following
DNA damage (Lowe et al, 1994). Additionally, p53 is involved in
the repair of DNA damage caused by various genotoxic stresses
and protects cells from death after irradiation (Caelles et al, 1994).
The p21 gene is a well-known mediator in the p53 signalling
pathway that induces G1 arrest, allowing time for damaged DNA to
be repaired (Xiong et al, 1993). A recently identified ribonucleotide
reductase, p53R2, is directly regulated by p53 for supplying
nucleotides to repair damaged DNA. The DNA synthesis in cells
arrested in G1 or G2 after DNA damage is mediated by p53R2
(Tanaka et al, 2000; Yamaguchi et al, 2001).
The aims of this retrospective study were to examine the
expression of p53, p53R2, and p21 in biopsy specimens of ESCC
and to evaluate whether such expression is useful for predicting
the response to CRT.
MATERIALS AND METHODS
Study groups
The present study involved 62 consecutive patients with advanced
ESCC who underwent CRT at the First Department of Surgery of
Kagoshima University Hospital between January 1995 and
December 2001. Of these patients, 36 underwent CRT followed
by oesophagectomy with lymph node dissection 4–6 weeks after
completing CRT, and 26 received only CRT. After all patients gave
informed consent, biopsy specimens of the primary tumours were
endoscopically collected. Classifications of the specimens were
determined according to the International Union against Cancer
tumour-node-metastasis (TNM) classification system (Sobin and
Wittwkind, 1997). All patients were followed up after discharge
with a radiographic examination every 1–3 months, computed
tomography every 3–6 months, and ultrasonography every 6
months. Follow-up data after surgery were available for all patients
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swith a median follow-up period of 20 months (range 1–70
months). The clinicopathologic features of the study group are
summarised in Table 1. All of the M1 tumours were due to distant
lymphnode metastases.
Chemoradiation therapy
A total radiation dose of 40Gy was applied; 2Gy fractions were
delivered 5 days per week for 4 weeks to the mediastinum and
neck. In the same period, chemotherapy was performed intrave-
nously using two anticancer agents: cisplatin (7mg over 2h) and 5-
FU (350mg over 24h).
The clinical response to CRT was evaluated by the findings of
oesophagography, oesophagoscopy, endoscopic ultrasonography,
and computed tomography. The clinical criteria for the response
were as follows (Japanese Society for Esophageal Diseases, 1999):
complete response (CR), disappearance of tumour and continuous
effect for more than 4 weeks; partial response (PR), response rate
more than 50% and no new lesions for more than 4 weeks; no
change (NC), response rate less than 50% or progressive disease
(PD) less than 25% and no new lesions for 4 weeks; and PD,
progressive disease more than 25% or appearance of new lesions.
The patients whose clinical effect was CR or PR were judged as
positively susceptible to CRT, whereas the patients with NC or PD
were judged as not susceptible.
The histological criteria for the response of CRT were as follows
(Japanese Society for Esophageal Diseases, 1999). Grade 0: Neither
necrosis nor cellular or structural changes can be seen throughout
the lesion. Grade 1: Necrosis or disappearance of the tumour is
present in no more than 2/3 of the whole lesion. Grade 2: Necrosis
or disappearance of the tumour is present in more than 2/3 of the
whole lesion, but viable tumour cells are still remaining. Grade 3:
The whole lesion falls into necrosis and/or is replaced by fibrosis,
with or without granulomatous changes. No viable tumour cells
are observed. In patients whose histological response was Grade 2
or 3, the CRT was judged to be effective. On the other hand, in
patients whose histological response was Grade 0 or 1, the CRT was
judged to be ineffective.
Immunohistochemistry
Tumour samples were fixed with 10% formaldehyde in phosphate-
buffered saline (PBS), embedded in paraffin, and sectioned into 4-
mm thick slices. After deparaffinisation of the sections, the
endogenous peroxidase was blocked by immersing the slides in a
0.3% hydrogen peroxidase–methanol solution for 30min at room
temperature. For staining with p53, p53R2, and p21 antibodies,
sections were pretreated with citrate buffer for 10min at 1001Ci na
microwave oven. The sections were washed with PBS for 5min
three times, and then blocked by treatment with PBS containing
3% skim milk for 30min at room temperature. The blocked
sections were incubated with the diluted primary antibody: p53
(DO7, Novocastra Laboratories, Newcastle upon Tyne, UK), 1:50;
p53R2 (sc-10840, Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA), 1:100; p21 (sc-817, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA), 1:100 with PBS at 41C overnight, followed by
staining with a streptavidin–biotin–peroxidase kit (Nichirei,
Tokyo, Japan). The sections were washed in PBS for 5min three
times, and the immune complex was visualised by incubating the
sections with diaminobenzidine tetrahydrochloride. They were
rinsed briefly in water, counterstained with haematoxylin, and
mounted.
Evaluation of immunohistochemistry was independently carried
out by two investigators (HO and SN). Regarding the immuno-
histochemical evaluation of p53 or p21, a distinct nuclear
immunoreaction in more than 10% of the cancer cells was judged
as p53 positive (p53 (þ)) or p21 positive (p21 (þ)) and in less
than 10% of the cancer cells as p53 negative (p53 ( )) or p21
negative (p21 ( )), according to our previously report (Natsugoe
et al, 1999). For p53R2, cytoplasmic immunoreaction in more
than 10% of the cancer cells was judged as p53R2 positive (p53R2
(þ)) and in less than 10% of the cancer cells as p53R2 negative
(p53R2 ( )).
In ESCC, immunohistochemically detectable p53 protein is
frequent due to mutation in the p53 gene, which results in the
formation of an abnormal protein with a prolonged half-life.
Therefore, p53 (þ) immunoreactivity is considered to be the
product of a mutated gene for p53, and p53 ( ) immunoreactivity
is associated with the wild-type p53 gene. (Wagata et al, 1993). On
the other hand, the p53R2 (þ) immunoreactivity indicates basal
p53R2 expression and p53R2 ( ) immunoreactivity is associated
to inactivation of p53R2 that is caused by intragenic mutation
(Byun et al, 2002).
Statistical analysis
Associations between two parameters were analysed with the
Spearman’s rank correlation test. A value of Po0.05 was
considered to be significant. Actuarial survival curves were
estimated using the Kaplan–Meier method, and differences in
survival between subgroups were compared with the log-rank test.
Multivariate analysis was made using Cox-hazard model analysis.
All statistical analyses were performed using the software package
StatViewt version 5.0 (Abacus Concepts, Berkeley, CA, USA).
RESULTS
Expression of p53, p53R2, and p21 in ESCC
The p53 and p21 expressions were detected as nuclear staining;
p53 had 43.5% positive expression and p21 had 54.8% positive
expression. The p53R2 expression was slight detectable in
perinuclear regions and distinct detectable in other cytoplasmic
regions; p53R2 had 37.1% positive expression (Figure 1).
Relationships between p53, p53R2, and p21 expressions
and response to CRT
The percentage for clinical response of CR, PR, NC, and PD was
1.6% (one out of 62), 69.4% (43 out of 62), 27.4% (17 out of 62),
and 1.6% (one out of 62), respectively. A total of 44 patients
(71.0%) with CR or PR were judged as effective, whereas 18
patients (29.0%) with NC or PD were judged as not effective. The
histological response rate of 36 patients was as follows: grade 1,
47.2% (17 out of 36 patients); grade 2, 30.6% (11 out of 36
patients); grade 3, 22.2% (eight out of 36 patients). In all, 19
patients (52.8%) with grade 2 or 3 were judged as effective, whereas
17 patients (47.2%) with grade 1 were judged as not effective.
Table 1 Characteristics of patients
Characteristics No.
Gender (male/female) 61/1
Age (years) 64 (48–77)
Tumour location
Upper/middle/lower 15/34/13
Histological type
Well/mode/poor 10/32/20
T
T1/T2/T3/T4 2/3/35/22
N
N0/N1 13/49
M
M0/M1 48/14
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sWhen comparing the relationship between the expression of p53 or
p53R2 and the clinical response to CRT, CRT was effective in
patients who had p53 ( ) tumours (P¼0.0001) or p53R2 ( )
tumours (P¼0.0013). However, no significant difference was
found between p21 expression and clinical effect (P¼0.70, data
not shown) (Table 2). When the correlation of p53, p53R2, and p21
expression with histological effect was analysed, CRT was effective
in p53 ( ) tumours (P¼0.041) or p53R2 ( ) tumours
(P¼0.0018), whereas p21 expression did not influence histological
effect (P¼0.68, data not shown) (Table 3).
Relationship between p53R2 expression and histological
response to CRT according to p53 expression
When the relationship between p53R2 expression and the
histological effect of CRT was analysed according to p53
expression, significant differences were found between the negative
expression of p53R2 and the histological effect of CRT in p53 ( )
tumours (P¼0.0014). Particularly, all patients with grade 3
tumours had p53 ( ) and p53R2 ( ) tumours. On the other
hand, p53R2 expression did not influence histological effect in p53
(þ) tumours (P¼0.15) (Table 4).
A
B
C
Figure 1 The expression of p53, p53R2, and p21 in oesophageal
squamous cell carcinoma. The positive expressions of p53 and p21were
found in the nuclei of cancer cells. The p53R2 expression was slightly
detectable in the perinuclear and other cytoplasmic regions. A:
p53( 400); B: p53R2 ( 400); C: p21( 400).
Table 2 Correlation of p53 and p53R2 expression with clinical response
to CRT
Clinical response to CRT (n¼62)
CR PR NC PD Total P
p53
(+) 0 12 14 1 27 0.0001
( ) 1 31 3 0 35
p53R2
(+) 0 12 10 1 23 0.013
( ) 1 31 7 0 39
p53(+)/( )¼p53 positive/negative expression; p53R2(+)/( )¼p53R2 positive/
negative expression; P-value was estimated as CR+PR vs NC+PD; CR¼complete
response; PR¼partial response; NC¼no change; PD¼progressive disease.
Table 3 Correlation of p53, p53R2 expression, and clinical response
with histological response to CRT
Histological response to CRT (n¼36)
Grade 1 Grade 2 Grade 3 Total P
p53
(+) 10 2 2 14 0.041
( )7 9 6 2 2
p53R2
(+) 10 2 0 12 0.0018
( )7 9 8 2 4
Clinical response
CR 0 0 0 0 0.0234
PR 10 10 8 28
NC 7 1 0 8
PD 0 0 0 0
p53(+)/( )¼p53 positive/negative expression; p53R2(+)/( )¼p53R2 positive/
negative expression; CR¼complete response; PR¼partial response; NC¼no
change; PD¼progressive disease.
Table 4 Correlation of combination p53 and p53R2 expression with
histological response to CRT
Histological response to CRT (n¼36)
Grade 1 Grade 2 Grade 3 Total P
p53 ( ) p53R2 ( ) 1 7 6 14 ] 0.0014
p53 ( ) p53R2 (+) 6 2 0 8
p53 (+) p53R2 ( ) 6 2 2 10 ] 0.15
p53 (+) p53R2 (+) 4 0 0 4
p53(+)/( )¼p53 positive/negative expression; p53R2(+)/( )¼p53R2 positive/
negative expression.
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or CRT response
When comparing the relationship between the expression of p53
and p53R2, and clinical outcome in 62 patients, the 5-year survival
rates of the patients with p53 ( ) and p53 (þ) tumours were 49.4
and 19.1%, respectively (P¼0.0011), and p53R2 ( ) and p53R2
(þ) tumours were 43.2 and 23.0%, respectively (P¼0.0057).
According to the clinical response to CRT, the 5-year survival rate
in patients with CRþPR and NCþPD tumours were 46.1 and
15.1%, respectively (P¼0.001). According to multivariate analysis,
although p53 and p53R2 expression was significant prognostic
factors, clinical response to CRT was not selected as a prognostic
factor (Table 5a).
When analysing clinical outcome according to p53, p53R2, and
pathological response to CRT in 36 patients who underwent
surgery, the 5-year survival rates of the patients with p53 ( ) and
p53 (þ) tumours were 59.2 and 23.1%, respectively (P¼0.0145),
p53R2 ( ) and p53R2 (þ) tumours were 50.6 and 33.3%,
respectively (P¼0.0399), and grade 2 or 3, and grade 1 tumours
were 71.4 and 23.5%, respectively (P¼0.0006) (Figure 2). Multi-
variate analysis revealed that only histological classification of
response to CRT was significant prognostic factor (Table 5b).
Additionally, when analysing clinical outcome according to p53,
p53R2, and clinical response to CRT in 24 patients who did not
undergo surgery, the 1- and 3-year survival rates of the patients
with p53 ( ) and p53 (þ) tumours were 55.4, 29.4 and 21.0, 0%,
respectively (P¼0.0095), p53R2 ( ) and p53R2 (þ) tumours were
62.9, 30.2 and 0, 0%, respectively (P¼0.0043), and CRþPR and
NCþPD tumours were 50.8, 27.1 and 16.7, 0% respectively,
(P¼0.0041) (Figure 3).
DISCUSSION
In the present study, we examined the expression of the proteins
p53, p53R2, and p21 in ESCC to determine whether such
expression was useful for predicting the response to CRT. This
study showed a significant correlation between p53 ( ) or p53R2
( ) expression and the clinical and histological effects of CRT. It
was previously reported that p53 expression is a good marker for
response to CRT in ESCC (Sarbia et al, 1998; Kishi et al, 2002).
Although p53 may play a critical role in radiation-induced
apoptosis, some patients with p53 ( ) tumours do not respond
well to CRT. A p53 ( ) condition in immunohistochemical
staining is associated with the wild-type p53 gene; however, some
p53 ( ) tumours with poor response to CRT may be associated
with a complete loss of p53 protein due to a p53-null mutation, an
acceleration of protein degradation (Hollstein et al, 1991), or the
existence of another molecule that regulates radiation sensitivity in
the p53 signalling pathway. Previously we reported that a
combination of p53 ( ) and p21 (þ) expressions is useful for
predicting the chemotherapeutic histological effect in ESCC
(Nakashima et al, 2000). However, in the current study, we could
not find a correlation between p21 (þ) expression and the clinical
Table 5 Risk factors affecting the overall survival rate determined by
univariate and multivariate analysis of p53, p53R2, and the clinical response
(a) or pathological response (b) to CRT in 62 and 36 ESCC patients,
respectively
P
Risk
Univariate Multivariate ratio 95% CI
(a)
p53 ( ) vs p53 (+) 0.0011 0.0215 2.688 1.157–6.250
p53R2 ( ) vs p53R2 (+) 0.0057 0.0185 2.469 1.164–5.235
CR+PR vs NC+PD 0.0009 0.2864 1.576 0.683–3.636
(b)
p53 ( ) vs p53 (+) 0.0145 0.1462 2.188 0.709–10.101
p53R2 ( ) vs p53R2 (+) 0.0399 0.3059 1.515 0.566–6.098
Grade 2, 3 vs Grade 1 0.0006 0.0466 4.176 1.025–26.824
p53(+)/( )¼p53 positive/negative expression; p53R2(+)/( )¼p53R2 positive/
negative expression; CRT¼chemoradiation therapy; CR¼complete response;
PR¼partial response; NC¼no change; PD¼progressive disease.
P = 0.0006
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Figure 2 Cause-specific survival curves for ESCC patients treated by
CRT and surgery (n¼36), according to the expression of p53, p53R2, and
pathological response. Survival curves were classified by p53 expression
(A), p53R2 expression (B), and pathological response (C). The 5 year
survival rates are indicated for each curve. P-values were calculated using
logrank tests.
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sand histological effects of CRT. This suggests that the mechanism
of cell death in CRT is different from that in chemotherapy.
The expression of p53R2 is induced by wild-type p53 in
response to various genotoxic stresses, including g-irradiation,
UV-irradiation, and exposure to anticancer drugs (Tanaka et al,
2000; Yamaguchi et al, 2001). DNA synthesis in cells arrested in G1
or G2 after DNA damage is mediated through the ribonucleotide
reductase activity of p53R2. For cell survival, p53 activated by DNA
damage then induces p53R2 expression to repair the damaged
DNA. For cell death, either severe DNA damage or inactivation of
the p53R2-dependent DNA synthesis pathway induces the
apoptosis signalling pathway to eliminate the unrepaired cells
(Tanaka et al, 2000). In the present study, p53R2 ( ) expression
was closely related to the clinical and histological effects of CRT.
The histological effect was predictable in 17 of 24 patients on the
basis of the p53R2 ( ) expression results of the biopsy specimens.
Furthermore, a positive response to CRT could be predicted in 13
of 14 patients (93%) on the basis of the combined results of p53
( ) and p53R2 ( ) expression (Table 4). These results suggest that
p53R2 has a DNA repair function downstream in p53. However,
four of 10 patients (40%) with both p53 (þ) and p53R2 ( )
expression responded well to CRT. This result suggests that some
tumours with a p53 mutation might be more susceptible to CRT
than tumours with wild-type p53, because a lack of wild-type p53
could not induce arrest at G1 and thus reduced the time for DNA
repair (Kastan et al, 1991; Vogelstein and Kinzler, 1992). Taken
together, our results suggest that a good response to CRT for ESCC
might be related to the efficiency of the DNA repair function in
cancer cells. In the future, we hope to develop a positive response
to CRT by inhibiting the function of DNA repair in ESCC.
Concerning the survival analysis, p53 ( ) and p53R2 ( ) were
good prognostic factors in all patients of this study (n¼62, study
group), even if these patients were divided into two; in the patients
treated with CRT followed by oesophagectomy (n¼36, surgical
group) and in the patients treated with only CRT (n¼26,
nonsurgical group). The clinical response to CRT was a prognostic
factor in this study group. However, in surgical group, the clinical
response to CRT was not selected as a prognostic factor although
the pathological response was sole prognostic factor. With regard
to discrepancy of prognostic factor between clinical and histolo-
gical response to CRT, the tumours with clinical PR was included
in various histological effects, grades 1, 2, and 3. In particular, 10
patients with clinical PR had grade 1 tumour by histological
examination (Table 3). Further detailed analysis should be
required in the discrepancy between clinical and histological
response to CRT.
In conclusion, p53 ( ) and p53R2 ( ) expression in biopsy
specimens of primary tumours is associated with a favourable
effect of CRT for ESCC. Patients displaying these expressions may
be good candidates for CRT. As immunohistochemical analysis of
biopsy specimens for p53 and p53R2 expression is a simple and
inexpensive test, these expressions should be evaluated before
treatment.
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